presentation semi-annual results 2013-2014 · diabetes direct business 1.2 -2.5 147.3 other -0.5...
TRANSCRIPT
Ypsomed – Presentation of 2013/14 Semi-Annual Results
Burgdorf, 5 November 2013
|
Important Notice
The information contained in this document has not been independently verified and no representation or warranty, express or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of Ypsomed Holding AG, its advisors or representatives, or their respective affiliates shall have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document. This document does not constitute, or form part of, an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.
This document contains forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as “may”, “plans”, “expects”, “believes” and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 2
|
Agenda
1. Introduction
2. Finance
3. Operational business
4. Outlook
5. Questions and answers
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 3
|
Ypsomed is reversing the trend
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 4
Total sales
Sanofi sales
2002/03 today tomorrow
|
Key figures1st HY 2013/14
In million CHF 1st HY 2013/14 1st HY 2012/13 Delta in %
Sales of goods and services 131.5 119.7 9.8
thereof Delivery Devices 68.4 69.1 -1.0
thereof Diabetes Direct Business 55.3 42.7 29.6
Thereof Other 7.7 7.9 -2.5
Gross profit 30.6 27.4 12.0
Gross profit in % 23.3% 22.8%
Operating profit 4.6 2.4 91.2
Operating profit in % 3.5% 2.0%
Net profit 4.6 2.0 125.8
Net profit in % 3.5% 1.7%
Research and development expenditures, total 11.2 10.2 9.6
Investments in fixed assets 10.1 8.1 24.9
Equity ratio in % 62.9% 63.6%
Employee headcount 989 1‘020 -3.0
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 5
|
Overview of the first half of the 2013/14 business year Ypsomed Delivery Systems
Delivery of the first batches of the Lupisulin pen for the Indian pharmaceutical company Lupin Ltd.
Tonghua Dongbao Pharmaceutical Co., Ltd. is launching the value, reusable Sulin pen on the Chinese market.
Launch of the Biosulin pen in South Africa by MJ Biopharm / Bioswiss.
Excellent foundations for profitable growth: customer project enquiries continue to increase.
Investments of CHF 10.1 million in new production plant such as automated pen assembly equipment and injection moulding tools.
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 6
|
Overview of the first half of the 2013/14 business year mylife™ Diabetescare The operating result (EBIT) is positive for the first time since the implementation of
the diversification strategy and expansion of diabetes care.
One of the main drivers for the strong growth in the retail business has been the high demand for the tubeless insulin pump mylife™ OmniPod®.
Growth rates compared with the same period last year:
- mylife™ OmniPod® more than doubled at 117%
- 24% in business associated with blood glucose meters
- 8% in the specialist diabetes retailer DiaExpert
Disinvestment of DiaExpert: We began this process in May 2013 and expect it to be completed within the next 6-8 months.
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 7
|
Outlook for mylife™ YpsoPump®
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 8
|
Agenda
1. Introduction
2. Finance
3. Operational business
4. Outlook
5. Questions and answers
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 9
|
Strong growth in the Diabetes Direct Business, driven by the mylife™ OmniPod®
In million CHF 2013/14 2012/13 Δ in %
Delivery Devices 68.4 69.1 -1.0
Diabetes Direct Business 55.3 42.7 29.6
Other 7.7 7.9 -2.5
Sales of goods and services 131.5 119.7 9.8
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 10
Net sales comprises: sales proceeds from delivery of goods, provision of research, development, industrialization and marketing services.
The Delivery Devices segment comprises the product groups pen systems, pen needles and other injection moulds manufactured by Ypsomed.
The Diabetes Direct Business segment covers the direct trade in a range of diabetes products via DiaExpert, including sales of mylife™ Pura®, mylife™ Unio®
blood glucose monitoring systems and mylife™ OmniPod® insulin patch pumps.
Other contains the precision-turned parts business segment (Ypsotec AG) and currently unused real estate for operational purposes.
|
Operational profit nearly doubled
In million CHF 2013/14 in % 2012/13 in %
Sales of goods and services 131.5 100.0 119.7 100.0
Cost of goods and services sold -100.8 -76.7 -92.4 -77.2
Gross profit 30.6 23.3 27.4 22.8
Marketing and sales expenses -20.3 -15.5 -19.4 -16.2
Administration expenses -6.7 -5.1 -6.4 -5.3
Other operating income 2.1 1.6 2.0 1.6
Other operating expenses -1.0 -0.8 -1.1 -0.9
Operating profit 4.6 3.5 2.4 2.0
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 11
Gross profit up due to better purchasing terms, especially in the retail business.
Operating profit nearly doubled thanks to very good results in DDB, especially due to demand for the mylife™ OmniPod®.
|
Diabetes Direct Business (DDB) now profitable following investment phase In million CHF 2013/14 2012/13 Δ in %
Delivery Devices 3.9 5.7 -30.8
Diabetes Direct Business 1.2 -2.5 147.3
Other -0.5 -0.8 39.0
Operating profit 4.6 2.4 91.2
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 12
For the future, we expect growth in sales and rising profitability in the "Delivery Devices" segment, thanks to newly launched pen systems and numerous customer enquiries and projects.
The DDB segment is now profitable after many years of market investment. The main driver is the mylife™ OmniPod®, but there has also been rapid growth in other products.
Positive signals from the market and efficiency savings in production should help ensure that the "Other" segment returns to profit in future.
|
EBITDA up
In million CHF 2013/14 in % 2012/13 in % Δ in %
Operating profit 4.6 3.5 2.4 2.0 91.2
Depreciation of fixed assets 9.2 7.0 9.7 8.1 -4.8
Amortization / Impairment of intangible assets 2.6 2.0 2.6 2.1 -
EBITDA 16.5 12.6 14.7 12.3 12.4
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 13
Depreciation and amortisation at same level as the previous year.
|
Financial result has positive effect on net profit
Financial income includes an adjustment on non-trading assets of CHF 1.0 million.
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 14
In million CHF 2013/14 in % 2012/13 in % Δ in %
Operating profit 4.6 3.5 2.4 2.0 91.2
Financial income 1.9 1.5 1.0 0.8 98.8
Financial expenses -1.5 -1.2 -1.0 -0.8 -59.3
Profit before income taxes 5.0 3.8 2.4 2.0 106.7
Income taxes -0.4 -0.3 -0.4 -0.3 -
Net profit 4.6 3.5 2.0 1.7 125.8
Earnings per share in CHF
(basic and diluted) 0.36 0.16
|
High levels of liquid assets
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 15
In million CHF 30.09.2013 in % 31.03.2013 in %
Assets
Cash and cash equivalents 14.9 4.3 9.6 2.8
Trade receivables 29.9 8.5 31.2 9.1
Other current assets 5.4 1.6 4.5 1.3
Prepayments and accrued income 7.5 2.1 6.2 1.8
Current income taxes 0.1 0.0 0.1 0.0
Inventories 52.5 15.0 56.6 16.6
Customer machinery 1.2 0.3 0.6 0.2
Total current assets 111.4 31.9 108.7 31.8
Financial assets 9.4 2.7 8.3 2.4
Deferred income tax assets 8.3 2.4 7.9 2.3
Fixed assets 162.4 46.5 161.7 47.3
Intangible assets 57.8 16.5 55.1 16.1
Total non-current assets 237.9 68.1 233.1 68.2
Total assets 349.3 100.0 341.8 100.0
|
Solid financing structure
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 16
In million CHF 30.09.2013 in % 31.03.2013 in %
Liabilities and equity
Financial liabilities 66.5 19.0 64.5 18.9
Trade payables 16.8 4.8 16.7 4.9
Prepayments from customers 2.7 0.8 2.1 0.6
Current income tax payable 1.4 0.4 2.0 0.6
Other payables 2.3 0.7 2.2 0.6
Accrued liabilities and deferred income 16.1 4.6 13.4 3.9
Provisions 0.6 0.2 0.6 0.2
Total current liabilities 106.4 30.5 101.4 29.7
Non-current liabilities to major shareholder 20.0 5.7 20.0 5.9
Other non-current financial liabilities 1.7 0.5 1.7 0.5
Provisions 1.0 0.3 1.0 0.3
Deferred income tax liabilites 0.5 0.2 0.4 0.1
Total non-current liabilities 23.3 6.7 23.1 6.7
Total equity 219.6 62.9 217.4 63.6
Total liabilities and equity 349.3 100.0 341.8 100.0
|
Ypsomed continues to invest in production sites in Switzerland
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 17
In million CHF 2013/14 2012/13
Cash Flow from operating activities 20.9 8.8
Purchases of financial assets - -0.3
Purchases of fixed assets -10.1 -8.1
Disposal of fixed assets 0.4 0.3
Purchases of intangible assets -5.3 -4.7
Cash Flow from investing activities -15.0 -12.8
Repayment of financial liabilities to major shareholder - -4.5
Proceeds from borrowings 2.0 14.5
Distribution of capital reserves -2.5 -2.5
Cost due to approved increase in share capital - -0.0
Cash Flow from financing activities -0.5 7.5
Effect of foreign currency translation -0.0 0.1
Total Cashflow 5.3 3.5
|
Agenda
1. Introduction
2. Finance
3. Operational business
4. Outlook
5. Questions and answers
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 18
|
Update on market and products
Injection systems – Ypsomed Delivery Systems
Diabetes care – mylife Diabetescare
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 19
|
Injection systems
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 20
|
Newly launched pen systems in the first half of 2013/14
21 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Market for injection systems Biosimilars
There are now a number of insulin biosimilars on the market in China, India and semi-regulated markets, made by local producers in vials (with no pen). Most local providers are converting to cartridges and pens.
Insulin biosimilars will not be available in Western Europe and the USA before 2015. This is because the expense of clinical trials and the lengthy EMA/FDA approval process and associated costs represent major hurdles.
There are a total of more than 30 biosimilars for other drugs, such as Humira/anti-TNF, GLP-1, hGH, FSH or PTH, in preparation worldwide. Some of these will be coming on to local or international markets over the next 3-5 years. Some of them are biobetters.
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 22
|
Market for injection systems Original products
New drugs primarily for treating autoimmune diseases such as polyarthritis, psoriasis, Crohn’s/IBD (Inflammatory Bowel Disease) or asthma. Injection systems are also required in oncology.
Not only are biobetters being developed but also new, long-lasting and more effective drugs in the traditional areas of treatment for self-injection: these include drugs for growth disorders, fertility treatment, multiple sclerosis, hepatitis and osteoporosis, as well as diabetes using new insulins and GLP-1s.
The specifications for the autoinjector or pen are increasing because, with the new drugs, patients no longer administer injections daily, but weekly or monthly. The high price of these drugs is also a factor. Therefore, the device has to be extremely user-friendly, to avoid handling errors.
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 23
|
Reusable injection systems
24 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Existing and potential customer projects for original products for reusable injection systems
25 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Existing and potential customer projects for biosimilars for reusable injection systems
26 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Single-use injection systems
27 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Existing and potential customer projects for original products for single-use injection systems
28 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Existing and potential customer projects for biosimilars for single-use injection systems
29 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Autoinjectors
30 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Existing and potential customer projects for original products for autoinjectors
31 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Existing and potential customer projects for biosimilars for autoinjectors
32 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Update on market and products
Injection systems – Ypsomed Delivery Systems
Diabetes care – mylife Diabetescare
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 33
|
Diabetes care
34 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
mylife™ Diabetescare product portfolio Overview of the main products
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 35
|
The complexity of European healthcare systems presents a challenge for the organisation of distribution
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 36
Sales via subsidiaries
Sales via distributors
|
The German system as an example of the complexity of European healthcare systems
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 37
• Healthcare funding system: Private health
insurance schemes (with tendency to
consolidate)
• Reimbursement of costs: Full reimbursement
of costs, usually a small excess, trend towards
flat-rate provision
• Marketing system: Doctors, pharmacies and
direct sales for diabetes aids
• Decision-makers: Doctors & patients. Fund
has little scope for intervention, therefore
expensive
|
The French system as an example of the complexity of European healthcare systems
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 38
• Healthcare funding system: State social
security
• Reimbursement of costs: Full
reimbursement of costs
• Marketing system: For insulin pumps and
accessories, via state accredited
intermediaries (préstataires). Everything else
via pharmacies, direct sales are not permitted
• Decision-makers: Intermediaries and
pharmacists. Doctors have very little influence,
so prices are subject to competition
|
The UK as an example of the complexity of European healthcare systems
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 39
• Healthcare funding system: State social
security. Since 2012, decentralised budget
responsibility in the different regions
• Reimbursement of costs: Full reimbursement
of costs; the number of pumps p.a. depends on
the funds available regionally
• Marketing system: Direct contracts with clinics
(pumps) and Clinical Commissioning Groups/
CCG (strips, needles). Few direct sales
• Decision-makers: Regionally over 200 CCGs in
a bidding process. Doctors, pharmacists,
patients and wholesalers are circumvented
|
Investment in retail pays off Trends in EBIT for the retail business DDB
40 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
Estimate for 2nd half of 2013/14 year. Scale is only an approximation of reality.
2. HY 1. HY 2. HY 1. HY 2. HY 1. HY 2. HY 1. HY 2. HY 1. HY 2. HY
2008/09 2009/10 2010/11 2011/12 2012/13 2013/14
Launch mylife™ Pura®
Launch mylife™ OmniPod®
|
Agenda
1. Introduction
2. Finance
3. Operational business
4. Outlook
5. Questions and answers
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 41
|
Outlook – financial year 2013/14
Growth in sales in the mylife™ Diabetescare business and the new pen systems that have been launched in various markets, and those due to be launched, make us very confident.
We are expecting growth in sales of about 10% and profit before interest and taxes (EBIT) of approx. CHF 10 million.
42 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Important dates
General meeting 1 Juli 2014
Presentation of annual figures 2013/14 27 Mai 2014
43 Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures
|
Agenda
1. Introduction
2. Finance
3. Operational business
4. Outlook
5. Questions and answers
Ypsomed Holding AG | Presentation of 2013/14 semi-annual figures 44
Questions and answers